CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays
PR96082
MONTREAL, May 19, 2022 /PRNewswire=KYODO JBN/ --
-- This acquisition solidifies CellCarta's leadership position in
proteomics services with a unique combination of validated set of
reagents and multiplex assays, including pathway specific
off-the-shelf panels, allowing for clinical protein quantification
covering a comprehensive range of immuno-oncology targets.
CellCarta, a leading global provider of precision medicine laboratory services,
announced today the acquisition of the commercial rights to the antibody panels
and assays from Precision Assays, a leader in next-generation targeted
proteomics testing solutions. A spin-off from Fred Hutchinson Cancer Center
("Fred Hutch"), Precision Assays develops and deploys high-end multiplex
quantitative immuno-MRM mass spectrophotometry-based assays for its
pharmaceutical and biotech industry clients.
Logo -
Logo -
The acquisition from Precision Assays of its large spectrum of targeted mass
spectrometry assays characterized according to the National Cancer Institute's
Clinical Proteomic Tumor Analysis Consortium (CPTAC) Tier 2 guidelines greatly
expands CellCarta's capabilities in off-the-shelf multiplex protein
quantification offerings ready for deployment in immuno-oncology clinical and
pre-clinical studies. "Precision Assays' large portfolio of robust assays
characterized according to CPTAC guidelines and its established proof of
concept data will enable CellCarta to confidently support its clients'
exploratory studies and therapeutic development strategies, offering them key
solutions to address important clinical challenges and move their
immuno-oncology programs forward. Given CellCarta's expertise in protein
quantitation, these immuno-MRM panels can further be validated to support
secondary and primary clinical endpoints" said Lorella Di Donato, Chief
Operating Officer of CellCarta, Immunology and Proteomics Divisions. Acquiring
Precision Assays' portfolio of validated assays strengthens CellCarta's growth
strategy to become the leading provider of precision medicine services and will
allow the organization to extend proteomics services from discovery to clinical
settings.
Based on technology licensed from Fred Hutch, Precision Assays' platform is
uniquely positioned to fully capture the unique advantages of multiplex protein
quantification using targeted mass spectrometry. Founder Dr. Amanda Paulovich,
a professor in the Clinical Research Division at Fred Hutch who holds the Aven
Foundation Endowed Chair, is an internationally recognized pioneer in targeted
mass spectrometry and a clinically trained oncologist. Dr. Paulovich has set
best-in-class standards to support precision medicine studies in
cancer-specific protein expression analysis in a variety of matrices from FFPE
cancer tissue biopsies to clinical serum-based samples. Precision Assays is one
of the few CROs to offer large and immuno-oncology relevant multiplex
off-the-shelf panels and is at the forefront of targeted-mass spec
proteomics-based research.
"As a global CRO with expertise in targeted mass spectrometry and specializing
in biomarker testing to support precision medicine, CellCarta is an ideal
partner to deploy and industrialize our platform to support discovery,
translational and clinical research, especially in precision medicine and
immuno-oncology", Paulovich said.
About CellCarta
CellCarta is a leading provider of specialized precision medicine laboratory
services to the biopharmaceutical industry. Leveraging its integrated
analytical platforms in immunology, histopathology, proteomics and genomics, as
well as related specimen collection and logistics services, CellCarta supports
the entire drug development cycle, from discovery to late-stage clinical
trials. The company operates globally with 11 facilities located in Canada,
USA, Belgium, Australia, and China.
For more information: cellcarta.com (
)
About Precision Assays
Precision Assays, LLC is a company based on technology licensed from Fred
Hutchinson Cancer Center. The company provides quantitative protein assays to
biotechnology and pharmaceutical partners.
CONTACT : CellCarta, Stephanie Bussières-Marmen, PhD, Manager, Global
Marketing, stephanie.marmen@cellcarta.com
Source - CellCarta
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。